Global Health Limited Cash Flow Conversion Efficiency
Global Health Limited cash flow conversion efficiency. Based on the latest financial reports, Global Health Limited (MEDANTA) has a cash flow conversion efficiency ratio of 0.089x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs3.29 Billion ≈ $35.53 Million USD) by net assets (Rs37.10 Billion ≈ $401.24 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Global Health Limited (2019–2026)
Cash flow conversion efficiency of Global Health Limited from 2019 to 2026. This chart illustrates how Global Health Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Global Health Limited stock price for real-time trading data and today's change.
Global Health Limited Cash Flow Conversion Ratio Explained
Global Health Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Global Health Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Global Health Limited ranked by their cash flow conversion efficiency. Also see Global Health Limited (MEDANTA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Figure Technology Solutions, Inc. Class A Common Stock
NASDAQ:FIGR
|
-1.593x |
|
Helmerich and Payne Inc
NYSE:HP
|
0.014x |
|
WesBanco, Inc.
NASDAQ:WSBC
|
0.019x |
|
Allreal Holding
SW:ALLN
|
0.034x |
|
Pulse Biosciences Inc
NASDAQ:PLSE
|
-0.188x |
|
Garrett Motion Inc
NASDAQ:GTX
|
-0.215x |
|
Atour Lifestyle Holdings Limited American Depositary Shares
NASDAQ:ATAT
|
0.247x |
|
Loomis AB ser. B
ST:LOOMIS
|
0.083x |
Annual Cash Flow Conversion Efficiency for Global Health Limited (2019–2026)
The table below shows the annual cash flow conversion efficiency of Global Health Limited from 2019 to 2026. Review Global Health Limited free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs39.84 Billion ≈ $430.88 Million |
Rs7.53 Billion ≈ $81.45 Million |
0.189x | +2.66% |
| 2025-03-31 | Rs33.88 Billion ≈ $366.35 Million |
Rs6.24 Billion ≈ $67.46 Million |
0.184x | -12.59% |
| 2024-03-31 | Rs29.06 Billion ≈ $314.23 Million |
Rs6.12 Billion ≈ $66.19 Million |
0.211x | -20.64% |
| 2023-03-31 | Rs24.28 Billion ≈ $262.60 Million |
Rs6.45 Billion ≈ $69.70 Million |
0.265x | +37.81% |
| 2022-03-31 | Rs16.16 Billion ≈ $174.77 Million |
Rs3.11 Billion ≈ $33.66 Million |
0.193x | +10.13% |
| 2021-03-31 | Rs13.82 Billion ≈ $149.50 Million |
Rs2.42 Billion ≈ $26.15 Million |
0.175x | +34.82% |
| 2020-03-31 | Rs13.50 Billion ≈ $145.95 Million |
Rs1.75 Billion ≈ $18.93 Million |
0.130x | +11.84% |
| 2019-03-31 | Rs13.31 Billion ≈ $143.93 Million |
Rs1.54 Billion ≈ $16.69 Million |
0.116x | -- |
About Global Health Limited
Global Health Limited, together with its subsidiaries, provides healthcare services in India. The company offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, emerg… Read more